AbbVie earned the European Commission's approval to acquire Allergan, with one condition.
What you should know:
1. The commission is requiring AbbVie to divest Allergan's brazikumab, an in-development inflammatory bowel disease product.
2. The commission wants the product divested to ensure development continues uninterrupted. The commission hopes the therapy will "increase the choice of treatments and offer better prices for patients."
3. AbbVie said it will divest the product to a company that will continue developing the drug.
4. AbbVie is acquiring Allergan for $63 billion.
More articles on surgery centers:
Alignment, standardization and sole-source partnership — How Mercy brought the Quadruple Aim to orthopedics
Orthopedic surgeon salary, hospital employment on the rise: 3 statistics
5 expert insights on outpatient joint replacements in 2019